The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | -27,259,804 | - |
| Increase (decrease) in accounts payable | - | 404,670 |
| Stock-based compensation expense | 852,757 | 229,725 |
| Represents the amount of operating lease right-of-use assets | 24,750 | 47,572 |
| Represents the amount of change in fair value of debentures | 383,823 | 200,000 |
| Repayment of debentures on extinguishment | -25,000 | - |
| Represents the amount of costs to issue debentures | 0 | 111,725 |
| Research and development expense (excluding acquired in process cost) | 8,717,475 | - |
| Foreign exchange gain/loss | -8,816 | - |
| Paid-in-kind interest | 89,680 | 0 |
| Represents the amount of gain loss on settlements | -157,721 | - |
| Net income (loss) attributable to parent | - | -11,278,492 |
| Represents the amount of increase decrease in costs related to settlements | 300,000 | - |
| Prepaid expenses | -430,723 | 113,201 |
| Deferred issuance costs | 0 | 0 |
| Increase (decrease) in accounts payable, trade | -380,033 | - |
| Increase (decrease) in accounts payable and accrued liabilities | -954,308 | 1,065,475 |
| Increase (decrease) in operating lease liability | -50,058 | -56,113 |
| Increase (decrease) in accounts payable, related parties | 21,807 | -21,186 |
| Net cash used in operating activities | -6,757,829 | -9,409,825 |
| Proceeds from issuance of common stock | 9,790,015 | - |
| Represents the amount of proceeds from issuance of shares under settlements | 5,097,005 | - |
| Proceeds from issuance of debentures | 7,366,293 | 4,500,000 |
| Repayment of new debenture | 5,637,709 | - |
| Proceeds from convertible debt | 0 | 0 |
| Proceeds from warrant exercises | 3,752,000 | 977,398 |
| Cash paid for financing costs in connection with sepa | - | 297,783 |
| Proceeds from stock options exercised | 162,400 | - |
| Represent the amount of proceeds from issuance of common shares and warrants | - | 9,790,015 |
| Costs to issue debentures | 136,726 | - |
| Represents the amount of proceed from costs to issue debentures | - | -54,582 |
| Issuance costs for common shares | 584,361 | - |
| Net cash provided by financing activities | 10,371,267 | 14,915,048 |
| Represents the amount of net cash paid for antev asset acquisition including transaction costs | 4,619,152 | - |
| Cash provided by (used in) investing activity, including discontinued operation | -4,619,152 | - |
| Effect of exchange rate on cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | -1,741 | - |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation | 4,497,768 | - |
| Cash and cash equivalents at beginning of period | 4,164,323 | - |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents, period increase (decrease), excluding exchange rate effect | - | 5,505,223 |
| Cash and cash equivalents at end of period | 8,662,091 | - |
Medicus Pharma Ltd. (MDCXW)
Medicus Pharma Ltd. (MDCXW)